Expert Review of Neurotherapeutics最新文献_第6页

The path to clinical application of human microglia transplantation for the treatment of CSF1R-related disorder. 人小胶质细胞移植治疗csf1r相关疾病的临床应用路径

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-14 DOI: 10.1080/14737175.2026.2672461

Tomasz Chmiela, Robert C Spitale, Zbigniew K Wszolek

{"title":"The path to clinical application of human microglia transplantation for the treatment of CSF1R-related disorder.","authors":"Tomasz Chmiela, Robert C Spitale, Zbigniew K Wszolek","doi":"10.1080/14737175.2026.2672461","DOIUrl":"10.1080/14737175.2026.2672461","url":null,"abstract":"Introduction: Colony Stimulating Factor 1 Receptor (CSF1R)-Related Disorder (CSF1R-RD) is a rare, rapidly progressive hereditary neurodegenerative microgliopathy caused by pathogenic variants in the CSF1R gene, leading to dysfunctional microglia. The disease presents with diverse, progressive neurological symptoms, including motor and cognitive decline, and has a poor prognosis.Area covered: This review critically examines the emerging therapeutic landscape for CSF1R-RD, with a primary focus on the disease-modifying potential of Hematopoietic Stem Cell Transplantation (HSCT). It synthesizes data from cohort studies and case reports, analyzing outcomes, neuroradiological changes, and the safety profile of HSCT. Furthermore, the review discusses the utility of advanced neuroimaging and fluid biomarkers, such as Neurofilament light chain (NfL) and Glial fibrillary acidic protein (GFAP), which are crucial for monitoring disease progression and evaluating therapeutic response.Expert opinion: Growing evidence supports HSCT as a disease-modifying strategy that can stabilize or slow progression, particularly when performed early in the symptomatic phase. However, HSCT's invasiveness and associated risks highlight the need for safer, more targeted interventions. The future of CSF1R-RD treatment lies in developing less invasive microglia replacement methods and enhancing engraftment efficacy, leveraging newly established clinical and biomarker tools for precise monitoring.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"653-664"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache. 苯腭神经节刺激治疗慢性丛集性头痛的安全性和有效性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-28 DOI: 10.1080/14737175.2026.2688942

Amy Gimson, Nasia Christou, Fiona Greenwood, Stefania Maniataki, Peter J Goadsby

{"title":"An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.","authors":"Amy Gimson, Nasia Christou, Fiona Greenwood, Stefania Maniataki, Peter J Goadsby","doi":"10.1080/14737175.2026.2688942","DOIUrl":"10.1080/14737175.2026.2688942","url":null,"abstract":"Introduction: Chronic cluster headache (CCH) is a very severe and disabling primary headache disorder characterized by frequent, unilateral attacks of excruciating pain accompanied by cranial autonomic symptoms without a substantial remission phase. A proportion of patients experience inadequate symptom control or intolerance to conventional therapies, highlighting the need for alternative treatment strategies.Areas covered: This narrative review highlights the anatomical and physiological rationale for sphenopalatine ganglion (SPG) stimulation and summarizes the available clinical evidence regarding its efficacy in acute and preventive treatment of CCH. Furthermore, this review also evaluates SPG's safety profile. This article is based on the currently available literature including data from randomized controlled trials, long-term follow-up studies, and real-world observational reports.Expert opinion: For patients with inadequate response or intolerance to traditional oral preventive options, neuromodulation is a practical alternative. There is both cohort and randomized controlled evidence establishing SPG stimulation efficacy in both acute and potentially preventive treatment of refractory cluster headache, although there is associated surgical risk with serious adverse events reported. SPG stimulation represents a promising option for carefully selected patients with refractory CCH, as an acute treatment, with a potential role in cluster headache prevention. Further controlled studies are needed to more clearly define optimal patient selection, long-term outcomes, and comparative effectiveness.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"677-686"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148344391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions. 基于当前和新出现的治疗难治性抑郁症的概念框架：机制演变、临床证据和未来方向。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-29 DOI: 10.1080/14737175.2026.2675008

Stephen Rush, Henry A Nasrallah

{"title":"A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions.","authors":"Stephen Rush, Henry A Nasrallah","doi":"10.1080/14737175.2026.2675008","DOIUrl":"10.1080/14737175.2026.2675008","url":null,"abstract":"Introduction: Treatment-resistant depression (TRD) represents an unmet challenge, accounting for disproportionate morbidity, disability, and healthcare burden in depression. Limitations of monoaminergic antidepressants have prompted a conceptual shift toward models emphasizing impaired neuroplasticity, synaptic dysfunction, and network dysregulation.Areas covered: This expert review synthesizes preclinical, translational, and clinical literature on depression pathophysiology from monoamine-based frameworks to models centered on synaptogenesis, glutamatergic signaling, neurotrophic regulation, inflammation, and brain networks. The authors outline a conceptual progression from monoaminergic models to neuroplasticity and synaptic remodeling and ultimately to network connectivity models of depressive illness, interpreting TRD treatments within this mechanistic framework. The authors review established and emerging treatments, including pharmacologic therapies, neuromodulation, antidepressants, and experimental plasticity-based interventions. Relevant literature was identified through PubMed and Google Scholar searches using terms related to treatment-resistant depression, neuroplasticity, ketamine, and neuromodulation, covering foundational studies through 2026.Expert opinion: TRD is conceptualized as impaired neural adaptability rather than neurotransmitter deficiency. Treatments reopening plasticity windows and recalibrating dysfunctional networks, such as ketamine, neuromodulation, and psychedelics, represent a paradigm shift in antidepressant development. The framework presented here is a conceptual synthesis rather than treatment guidelines, and prospective studies are needed to determine how mechanistically informed models can be validated and applied clinically.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"631-652"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis. 星形细胞肿瘤的鉴别诊断及其对治疗和预后的影响。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-23 DOI: 10.1080/14737175.2026.2688939

Rob Dickerman, Mathew Mendoza, Makayla McClinton, Gwen Champion, Joneshia Runnels, Ha'nai Hudson

{"title":"The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.","authors":"Rob Dickerman, Mathew Mendoza, Makayla McClinton, Gwen Champion, Joneshia Runnels, Ha'nai Hudson","doi":"10.1080/14737175.2026.2688939","DOIUrl":"10.1080/14737175.2026.2688939","url":null,"abstract":"Introduction: The most common cell type in the central nervous system (CNS), astrocytes, is also the cell type most commonly associated with the brain cancer called astrocytoma. Advances in genetic/molecular techniques led to the 2021 CNS tumor reclassifications. In this review, we will simplify the somewhat complex 2021 neuropathological diagnostic algorithm and transition into a discussion on uncommon treatment options and the biochemical basis for their applications.Areas covered: Herein, the authors review the most common new CNS tumor classifications based on histological and genetic alterations. Treatment and prognosis of these tumors change as the diagnostic capabilities improve. The literature utilized to complete this manuscript was collected through www.pubmed.gov, from the years 1924-2026. The search focused on astrocytomas, neuropathology criteria, molecular/genetics of, and treatment options.Expert opinion: Neuropathology is crucial for providing guidance to the neurosurgeons operating, oncologists and radiation oncologists treating, and most importantly the patients and families that go through these treatments. Neuropathology ultimately provides the most important first step in determining the treatment flow chart, thus the proper identification/diagnosis with a detailed genetic profile of the tumor enhances insight on the treatment and prognostic expectations. Our ability to better understand the genetic/molecular alterations occurring in CNS tumors leads us to better treatments and hopefully eventual cures.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"665-675"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treating the root cause of tension-type headache: when analgesics address the symptom but not the disorder. 治疗紧张性头痛的根本原因：当镇痛剂解决症状而不是疾病。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-05 DOI: 10.1080/14737175.2026.2668457

Modar Khalil, Fayyaz Ahmed

引用次数: 0

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder? 白细胞介素-6受体拮抗剂如何影响视神经脊髓炎谱系障碍的未来？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-06 DOI: 10.1080/14737175.2026.2669297

Murat Kürtüncü

引用次数: 0

Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates: a plain language summary of publication. 每晚一次羟酸盐的剂量偏好和每晚两次羟酸盐的夜间体验：出版物的简明语言摘要。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-20 DOI: 10.1080/14737175.2026.2668473

Asim Roy, Thomas Stern, John Harsh, Bruce C Corser, Adrian Santamaria, Brian Abaluck, Sally Ibrahim, Katie Lancaster, Jennifer Gudeman

引用次数: 0

Cognitive and motivational therapy for problematic alcohol use and alcohol use disorder in older adults: a systematic review. 认知和动机疗法对老年人酒精使用问题和酒精使用障碍的治疗：一项系统综述

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-30 DOI: 10.1080/14737175.2026.2665653

Jennifer J Park, Kangxin Zhang, Goeun Lee, Marcus Lee, Anika Mohapatra, Marc N Potenza

{"title":"Cognitive and motivational therapy for problematic alcohol use and alcohol use disorder in older adults: a systematic review.","authors":"Jennifer J Park, Kangxin Zhang, Goeun Lee, Marcus Lee, Anika Mohapatra, Marc N Potenza","doi":"10.1080/14737175.2026.2665653","DOIUrl":"10.1080/14737175.2026.2665653","url":null,"abstract":"Introduction: Cognitive and motivational therapies for alcohol use disorder (AUD) and problematic alcohol use have demonstrated effectiveness in youth and general adults, yet evidence specific to older adults has not been synthesized. This systematic review summarizes cognitive and motivational interventions in older adults.Methods: PubMed, PsycINFO, Embase, and Web of Science were searched. Eligible studies included participants aged ≥55 years with AUD or problematic alcohol use and evaluated cognitive or motivational therapies. Studies without alcohol-related outcomes were excluded. The Effective Public Health Practice Project Quality Assessment Tool was used.Results: Seven studies involving 1121 participants were identified. Motivational approaches were most common (4/7 studies; 813 participants, 72.5%), whereas combined cognitive-motivational approaches (1/7 studies; 158 participants, 14.1%), CBT-like approaches (1/7 studies; 60 participants, 5.4%), and other non-motivational cognitive interventions (1/7 studies; 90 participants, 8.0%) were represented by single studies. Treatments generally improved alcohol-consumption-related outcomes, although comparative efficacy was less clear. Although cognitive and motivational therapy for AUD and problematic alcohol use in older adults appear promising, definitive conclusions cannot be drawn as evidence is limited by methodological concerns including limited and heterogeneous evidence from randomized controlled trials, small sample sizes, limited long-term follow-up, and insufficient reporting of intervention components.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"585-596"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The postpartum period and bipolar disorder: early identification, prevention, and management. 产后与双相情感障碍：早期识别、预防和管理。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-01 DOI: 10.1080/14737175.2026.2653163

Verinder Sharma

{"title":"The postpartum period and bipolar disorder: early identification, prevention, and management.","authors":"Verinder Sharma","doi":"10.1080/14737175.2026.2653163","DOIUrl":"10.1080/14737175.2026.2653163","url":null,"abstract":"Introduction: New-onset or worsening bipolar disorder is common after childbirth and is associated with increased risk of psychiatric hospitalization, along with safety concerns for the mother and newborn. Despite the availability of several medications, preventing postpartum bipolar mood episodes remains difficult.Areas covered: This narrative review outlines findings of a search of MEDLINE/PubMed, PsycINFO, and the Cochrane Database of Systematic Reviews in November 2025. The author examines the challenges of preventing postpartum mood episodes in women with bipolar disorder and discusses opportunities for early detection and treatment of symptoms during and after pregnancy. Continuation of optimized maintenance treatment to mitigate the risk of recurrence associated with weaning and resumption of menstruation is emphasized. This review also highlights research gaps, particularly the lack of treatment studies.Expert opinion: Efforts to prevent postpartum episodes of bipolar disorder should include timely identification of at-risk individuals, confirming diagnosis and psychiatric comorbidities, reviewing illness course, and analyzing risk and protective factors, psychoeducation, mitigating risk factors, vigilant monitoring for emerging symptoms of relapse or recurrence, tailoring treatment, assessing breastfeeding safety and compatibility, and addressing safety concerns. Follow-up should continue for several months, as mothers remain at risk of relapse during weaning, resumption of menstruation, and the return to work after maternity leave.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"555-567"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the pharmacological management of early motor manifestations of Parkinson's disease (PD). 帕金森病（PD）早期运动表现的药理治疗进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-03-18 DOI: 10.1080/14737175.2026.2645845

Thomas Müller, Willibald Kohlhepp

{"title":"Advances in the pharmacological management of early motor manifestations of Parkinson's disease (PD).","authors":"Thomas Müller, Willibald Kohlhepp","doi":"10.1080/14737175.2026.2645845","DOIUrl":"10.1080/14737175.2026.2645845","url":null,"abstract":"Introduction: Parkinson's disease (PD) is a heterogeneous, chronic neurodegenerative disorder. Once the diagnosis is made, symptomatic dopamine substituting therapy is initiated.Areas covered: This narrative review discusses exemplary past and recent failed attempts.Expert opinion: The diagnosis of PD at the onset of motor symptoms is already late in terms of disease progression. An easy-to apply, reliable, sensitive diagnostic biomarker for predictive screening is currently outstanding. Nevertheless, the ability to delay progression and/or cure of the disease is currently the greatest unmet need. Chronic neurodegenerative processes arise from various distinct yet interconnected metabolic and pathological cascade sequences that work together. The translation of promising treatments concepts for beneficial disease modification has failed once they were tested in levodopa-naive patients. Microbiome alteration with short fatty acids or acetyl-DL-leucine supplementation, only enhance levodopa efficacy, But do not modify disease progression in a benefical way. Presently, there is also a lack of real innovation in terms of dopamine substitution.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"547-554"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0